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Abstract
Purpose: We investigated whether serum interleukin (IL)-8 reflects the tumor
microenvironment and has prognostic value in patients with oral squamous cell
carcinoma (OSCC).
Experimental Design: Fifty OSCC patients who received radical resection of their
tumor(s) were enrolled. Preoperative sera were measured for IL-8 by ELISA.
Expression of IL-8 and the infiltration of immune cells in tumor tissues were
analyzed by an immunohistochemical staining of surgical specimens.
Results: We found that disease-free survival (DFS) was significantly longer in the
Stage I/II OSCC patients with low serum IL-8 levels compared to those with high
levels (p50.001). The tumor expression of IL-8, i.e., IL-8(T) and the density of
CD163-positive cells in the tumor invasive front, i.e., CD163(IF) were correlated
with the serum IL-8 level (p50.033 and p50.038, respectively), and they were
associated with poor clinical outcome (p50.007 and p50.002, respectively, in DFS)
in all patients. A multivariate analysis revealed that N status, IL-8(T) and CD163(IF)
significantly affected the DFS of the patients. Further analysis suggested that
combination of N status with serum IL-8, IL-8(T) or CD163(IF) may be a new
criterion for discriminating between OSCC patients at high and low risk for tumor
relapse. Interestingly, the in vitro experiments demonstrated that IL-8 enhanced
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generation of CD163-positive M2 macrophages from peripheral blood monocytes,
and that the cells produced IL-10.
Conclusions: These findings indicate that IL-8 may be involved in poor clinical
outcomes via generation of CD163-positive M2 macrophages, and that these
factors in addition to N status may have prognostic value in patients with resectable
OSCSS.
Introduction
Head and neck squamous cell carcinoma (HNSCC) represents the fifth most
frequently occurring cancer worldwide. Of the 1.6 million diagnoses and 333,000
deaths each year worldwide due to HNSCC, one-half are localized in the oral
cavity [oral squamous cell carcinoma (OSCC)] [1]. Despite recent advances in
surgery, radiotherapy and chemotherapy, the 5-year survival rate for patients with
OSCC has remained at 50% for the past 30 years [2]. The treatment for patients
with early-stage OSCC (Stage I or II) as well as for those with advanced OSCC
(Stage III or IV) is mainly surgical resection. The desired improvement in the
efficacy of treatment for OSCC will be aided by the identification of biomarker(s)
that can identify the subpopulation of OSCC patients who are at high risk of
tumor relapse, and by the development of effective treatments for these high-risk
patients. Although Tumor-Node-Metastasis (TMN) classification-based staging is
an important prognostic factor in OSCC patients, the prognosis is not satisfactory
even in early-stage patients, and high-risk patients who are Stage I/II OSCC might
be missed based on the TNM staging [3–6].
We have reported the prognostic significance of the expression ratio of the
genes for the anti-apoptotic protein Bcl-2 and the pro-apoptotic protein Bax in
circulating immune cells, and we found that the immunological status might be
critical to the clinical outcome of patients with head and neck cancer [7].
However, the usefulness of this information is not yet confirmed because it is still
unknown what tumor microenvironment is reflected by this immunological
condition of the peripheral blood. The immune status in a tumor microenvir-
onment is closely associated with the clinical outcomes of patients with
malignancies [8.9]. The migration of the T cells positive for CD3, CD8 or FOXP3
into the tumor sites was reported to be correlated with the outcome of patients
with several types of malignancies (i.e., ovarian, colorectal, and breast cancer as
well as head and neck cancer) [8.9]. If a patient’s peripheral blood profile reflects
the microenvironment of his or her tumor, it may be possible to estimate the
immune status of the tumor microenvironment and to predict the patient’s
clinical outcome by evaluating the immunological state of the peripheral blood. In
fact, a recent study demonstrated that pre-therapeutic plasma interleukin (IL)-6
levels were correlated with the expression of nuclear factor (NF)-kB in the nuclei
of tumor cells as well as the expression of IL-6 in local tumor sites, and that the
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plasma IL-6 level is an independent negative prognostic factor for overall survival
(OS) of patients with castration-resistant prostatic carcinoma [10]. Motomura et
al. reported that the pre-operative neutrophil-lymphocyte ratio (NLR) reflects
hepatocellular carcinoma (HCC) recurrence after liver transplantation via an
inflammatory tumor microenvironment [11]. Serum factor(s) that reflect the
immune status of the tumor microenvironment may be useful prognostic
biomarker(s).
We previously examined sera derived from OSCC patients for multiple
cytokines by using a multiplexed measurement system [12], and the results
showed that the serum IL-8 level tended to negatively correlate with favorable
outcome in these patients (authors’ personal communications). In the present
study, we expanded the number of patients with resectable OSCC, measured their
sera for circulating IL-8 by an enzyme-linked immunosorbent assay (ELISA)
which is more quantitative than the multiplexed measurement system, and
compared the serum IL-8 levels with the clinical outcomes of the patients. In
addition, to determine whether circulating IL-8 levels reflect the tumor
microenvironment, especially the immunological microenvironment, we used
immunohistochemical staining to analyze the expression of IL-8 as well as the
infiltration of immune-inhibitory cells such as Foxp3-positeve regulatory T cells
(Tregs) and CD163-positive M2 macrophages, which may be adverse prognostic
markers [8, 9, 13].
Materials and Methods
Patients
This study was carried out in accord with the standards of our Institutional
Committee for the Protection of Human Subjects. We have read the Helsinki
Declaration and have followed the guidelines in this investigation. Informed
written consent was obtained from all patients, and the collection of the samples
was approved by the Institutional Review Board of Ehime University Hospital
[IRB approval No. 1308006 (Title: A search of factors influencing the decrease of
host immunity in patients with oral squamous cell carcinoma and No. 1309015
(Title: An analysis for the mechanism of the inhibition of host immunity in
patients with oral malignancies)]. From April 2006 to March 2010, 50 OSCC
patients (32 males and 18 females) who received radical resection of their
tumor(s) at the Division of Oral and Maxillofacial Surgery, Ehime University
Hospital were enrolled in this study. A summary of the patients’ profiles is given
in Table 1. The histological differentiation of the tumors was classified in accord
with the WHO classification. The mode of cancer invasion was classified into five
grades according to the classification proposed by Yamamoto and Kohama (YK
classification): YK-1, well-defined border; YK-2, cords, less marked border; YK-3,
groups of cells, no distinct border; YK-4C; diffuse invasion, cord-like type; and
YK4-D, diffuse invasion, widespread type [14]. To evaluate the nutritional
conditions of the OSCC patients, we used the Prognostic Nutritional Index
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(PNI5106serum albumin (g/dl) +0.0056total lymphocytes counts (/mm3))
[15].
Table 1. The clinicopathological characteristics of the OSCC patients.
p value
Serum IL-8 IL-8 (T) CD163 (IF)
Numbers of
patients
50
Age 68.6 (range: 48–93) 0.557 1.000 1.000
Sex Male 32 (64%) 0.768 0.764 0.769
Female 18 (36%)
Stage I 9 (18%) 0.077 0.773 1.000 Stage I/II vs Stage III/
IV
II 18 (26%)
III 4 (8%)
IV 19 (38%)
T 1 10 (20%) 0.199 1.000 0.127 T1/2 vs T3/4
2 25 (50%)
3 3 (6%)
4 12 (24%)
N 0 32 (64%) 0.540 0.130 0.377
1–3 18 (36%)
M 0 50 (100%) NA NA NA
1 0 (0%)
Histological
differentiation
well 40 (80%) 1.000 0.722 0.074 well vs non-well
moderate 8 (16%)
poor 2 (4%)
Mode of cancer
invasion
YK-1 0 (0%) 0.494 0.175 0.171 YK-1,2,3 vs YK-4
YK-2 5 (10%)
YK-3 34 (68%)
YK-4C 10 (20%)
YK-4D 1 (2%)
Primary sites Tonge 17 (34%) 0.748 0.802 1.000 Tongue vs gingiva
Upper gingiva 7 (14%)
lower gingiva 16 (32%)
Buccal mucosa 6 (12%)
Floor of the mouth 3 (6%)
mandiblar bone 1 (2%)
The mode of cancer invasion was classified into five grades according to the classification proposed by Yamamoto and Kohama (YK classification).
NA: not analyzed.
doi:10.1371/journal.pone.0110378.t001
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Serum collection and IL-8 ELISA
Before the patients’ surgery, their sera were collected and immediately frozen at
280 C˚ until the assay for IL-8. We analyzed the serum IL-8 levels using a human
CXCR8/IL-8 Quantikine ELISA kit (R&D Systems, Minneapolis, MN, USA)
according to the manufacturer’s protocol. The cut-off value 7.5 pg/ml was chosen
based on the sensitivity of the ELISA Kit and the receiver operating characteristic
(ROC) curve. The serum IL-8 levels of healthy donors [5 males and 3 females,
mean of ages 59.2 (range: 48–70)] were undetectable. Informed written consent
was also obtained from all healthy donors.
Immunohistochemical staining
The surgically resected OSCC specimens were fixed in phosphate-buffered 10%
formalin and embedded in paraffin, and then a series of tissue sections (4 mm
thick) were prepared from each sample. Immunohistochemical staining was
performed by the avidin-biotin-peroxidase complex method. Briefly, the sections
were deparaffinized, pretreated with 10 mM citrate buffer (pH 6.0) in an
autoclave at 121 C˚ for 20 minutes, and incubated with 0.3% H2O2 in distilled
water for 10 minutes to block endogenous peroxidase activity. The sections were
then incubated overnight at 4 C˚ with each specific monoclonal antibody to
human IL-8 (diluted 1:50, DAKO, Glostrup, Denmark), to human Foxp3 (diluted
1:100, eBioscience, San Diego, CA), and to human CD163 (diluted 1:200,
Novocastra, Newcastle, UK). After washing, the sections were overlaid with
biotinylated anti-mouse antibody (Vector Laboratories, Burlingame, CA) at room
temperature for 60 minutes and then washed in phosphate-buffered saline (PBS),
followed by labeling with streptavidin-peroxidase complex (Vector Laboratories).
The peroxidase reaction was developed with 393-diaminobenzidine as a
chromogen. The sections were counterstained with hematoxylin, dehydrated with
ethanol, treated with xylene and enclosed in synthetic resin. Quantitative studies
of the immunohistochemically stained sections were performed by pathologists in
a blind fashion by evaluating three randomly chosen fields in each sample.
Individual cells were counted under microscopic fields. The cells stained with
anti-IL-8 antibody were counted on tumor cells (IL-8(T)) and on stromal cells
(IL-8(S)) in tumor tissues, and the cases in which over 5% of the cells were
stained, were defined as positive expression (+). We counted the numbers of
Foxp3- or CD163-stained immune cells that had infiltrated into the tumor
(Foxp3(IT) or CD163(IT)) and those that had infiltrated the tumor invasive front
(Foxp3(IF) or CD163(IF)) by using BIOREVO BZ-9000 (Keyence, Elmwood Park,
NJ), and each median value was chosen as the cut-off value.
Generation of CD163-positive M2 macrophages in vitro and the
flow cytometric analysis of cell surface CD163 expression
The induction of CD163-positive M2 macrophages in vitro was carried out
following the method of Durafurt et al [16]. In brief, healthy donor-derived
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PBMCs (56106/ml) prepared by the standard Ficoll-Hypaque gradient density
centrifugation method were placed in 100-mm plastic tissue culture dishes
(Becton Dickinson Labware, Franklin Lakes, NJ) in RPMI 1640 medium
supplemented with 10% heat-inactivated FBS. After 3 hours of incubation at 37 C˚,
nonadherent cells were removed, and the adherent cells were treated with
recombinant human macrophage-colony stimulating factor (M-CSF) (25 ng/ml;
PeproTech, Rocky Hill, NJ) for 5 days, and then were stimulated with
recombinant human IL-4 (20 ng/ml, Invitrogen, Carlsbad, CA) and recombinant
human IL-13 (20 ng/ml, PeproTech) for 2 days. We found previously by a flow
cytometric analysis that the population of adherent cells remaining in the wells
was composed of .95% CD14+ monocytes [17]. To examine whether IL-8
enhance the generation of M2 macrophages, 10 ng/ml of recombinant human IL-
8 (R&D Systems) instead of IL-4 and IL-13 was added into the culture after 5 days
of cultivation with M-CSF. We have already examined the dose dependency of IL-
8 in IL-10 production in the preliminary study. IL-10 production showed the peal
level in 10 ng/ml of IL-8 among the several concentrations (100 pg/ml, 1 ng/ml,
10 ng/ml and 100 ng/ml), and therefore 10 ng/ml of IL-8 was used in the current
experiments. After 2 days, we evaluated the cell-surface expression of CD163 using
a flow cytometric analysis, and measured the culture supernatants for IL-10 by
ELISA (R&D Systems). Monoclonal antibodies for CD163 as well as for CD206
which is another marker of M2 macrophage and an isotype-matched control
mouse IgG conjugated with fluoresceine-isothiocyanate (FITC) were purchased
from PharMingen (San Diego, CA). The cells were resuspended in PBS containing
0.1% sodium azide and 0.2% bovine serum albumin and were then incubated for
30 minutes at 4 C˚ with a saturating concentration of each monoclonal antibody
according to the manufacturer’s instructions. After the cells were washed twice,
their fluorescence intensity was determined using a flow cytometer (EPICS XL-
MCL, Beckman Coulter, Fullerton, CA).
Statistical analysis
We used Kaplan-Meier curves and log-rank tests to assess the differences in
survival times between the treatment groups. A multivariate analysis was
performed to evaluate the impact of factors in survival using Cox’s proportional
hazards regression model. The differences between the two groups of categorical
data were analyzed by two-sided Fisher’s exact test. In the in vitro experiments, we
evaluated the data using Student’s two-tailed t-test. Values of P,0.05 were
considered significant.
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Results
Relationship between the clinicopathological characteristics of
OSCC patients and serum IL-8 levels, IL-8 expression in the
tumors and CD163-positive cell infiltration into the tumor invasive
front
The immunohistochemical staining showed IL-8 expression in the tumor cells
(IL-8(T)); most of the IL-8 expression in tumor tissues was observed in tumor
cells but not tumor stromal cells. Very weak staining of IL-8 was observed in
tumor stromal cells in 11 of 50 cases. However, no significant relationship to
clinical outcome (DFS and OS) was observed (data not shown). Since the
infiltration of CD163-positive cells into the tumor invasive front (CD163(IF)) but
not the intra-tumor site (CD163(IT)) was strongly correlated with clinical
outcomes (Overall survival [OS] and disease-free survival [DFS]) of the OSCC
patients as described below, we present only the data of CD163 (IF) herein. In
addition, the migration of Foxp3-positive cells into the tumor tissues was not
significantly correlated with the OS as well as DFS (data not shown), and thus the
data obtained with Foxp3-staining are not shown in this report.
We found no significant relationship between age, gender, TNM classification,
histological differentiation, mode of cancer invasion, or primary site with serum
IL-8, IL-8(T) and CD163(IF). The serum IL-8 levels tended to be high in the 23
patients with advanced-stage (Stage III/IV) of OSCC compared to the 27 early-
stage (Stage I/II) patients, although no significant relationship was observed
(P50.077) (Table 1).
Relationship between the OS and DFS of OSCC patients and
serum IL-8, IL-8 expression in tumor, and CD163-positive cell-
infiltration into the tumor invasive front
Among the 50 OSCC patients, the 18 patients with low levels of serum IL-8 tended
to be long survivors (P50.234 in OS, P50.079 in DFS), but a significant
difference was not observed. Among the 27 Stage I/II patients, the DFS of the
patients with low serum IL-8 levels were significantly longer than those of the
patients with high serum IL-8 (P50.010), and in all of the Stage I/II patients with
low IL-8, there have been no relapse events as of this writing. Among the 23 Stage
III/IV patients, no significant relationship between the serum IL-8 level and
clinical outcome (P50.825 in OS, P50.449 in DFS) was observed, as most of the
patients with advanced OSCC (18 of the 23 patients) showed high levels of IL-8 in
their sera (Fig. 1).
We examined the expression of IL-8 in tumor cells (IL-8(T)) and CD163-
positive cell-infiltration into the tumor invasive front (CD163(IF)) by
immunohistochemical staining. Upper panel of Fig. 2A demonstrated a case who
showed IL-8(T)(+) and CD163(IF)High. Fig. 2A lower panel showed a rare case
who showed IL-8(T)(2) and CD163(IF)High. Any factor(s) except for IL-8 might
play a role for migration of CD163-positive cells. We analyzed their relationships
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with the patients’ clinical outcome. In 16 of the 19 IL-8(T)(+) cases, CD163-
positive cells migrated to the tumor invasive front in proximity to cancer cells
expressing IL-8 (Fig. 2A, upper panel). The OS and DFS of the IL-8(T)(2)
patients were significantly longer than those of the IL-8(T)(+) patients (P50.043
in OS, P50.007 in DFS). The patients with low CD163(IF) showed longer OS and
DFS compared to the patients with high CD163(IF) (P50.006 in OS, P50.002 in
DFS) (Fig. 2B). In these cases, 15 of 16 IL-8T(+)CD163(IF)High patients showed
high serum IL-8, and only 1 case low serum IL-8 (data not shown).
Correlation of the mode of relapse with serum IL-8, IL-8(T) and
CD163(IF)
Serum IL-8, IL-8(T) and CD163(IF) were each significantly correlated with post-
operative cervical lymph node (LN) metastasis (P50.018, P50.001 and P50.023,
respectively). Although no significant relationship was observed, IL-8(T) and
CD163(IF) also tended to be correlated with local recurrence (P50.089 and
Figure 1. The relationship between serum IL-8 levels and the clinical outcome in OSCC patients who underwent radical resection of their tumor(s).
The differences in the serum IL-8>7.5 pg/ml vs. IL-8,7.0 pg/ml in all patients, in the Stage I/II patients and in the Stage III/IV patients were calculated by log-
rank test. *P,0.05. NA: not analyzed because the number of OS events was only one.
doi:10.1371/journal.pone.0110378.g001
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P50.098, respectively) (Table 2). Only T status was significantly related to local
recurrence (p50.002) (Table 2); the frequency of post-operative LN metastasis
Figure 2. Relationship between IL-8 expression, CD163-positive cell-infiltration in tumor tissues and clinical outcome of OSCC patients. (A)
Immunohistochemical staining for IL-8 and CD163. Most of the IL-8-positive cells were tumor cells, not stromal cells in tumor tissues. CD163-positive cells
had infiltrated into the tumor invasive front but not the intra-tumor region. (B) Differences in IL-8(T)(+) vs. IL-8(T)(2) and CD163(IF)High vs. CD163(IF)Low in
OS and DFS in OSCC patients, calculated by log-rank test. *P,0.05.
doi:10.1371/journal.pone.0110378.g002
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was not correlated with T status (Table 2) or with the mode of invasion (data not
shown).
Correlations among serum IL-8, IL-8(T) and CD163(IF)
In all patients, a significant correlation was observed between serum IL-8 levels
and IL-8(T) (p50.033), and this correlation was much stronger in the early-stage
OSCC patients (p50.018). No such correlation was observed in the patients with
advanced OSCC (p50.621) (Table 3). A similar correlation or tendency was
observed between serum IL-8 and CD163(IF) (p50.038 in all patients, p50.021 in
Stage I/II patients, and p50.640 in Stage III/IV patients) (Table 3). A marked and
significant relationship between IL-8(T) and CD163(IF) was observed in all 50
patients (P50.0003) (Table 3).
We analyzed the relationship between the expression of IL-8 in tumor cells, i.e.,
IL-8(T) and the patients’ peripheral blood data and found that there was a
significant correction between IL-8(T) and the circulating C-reactive protein
(CRP) level (P50.001) (Data not shown). The serum IL-8 level was correlated
with CRP only in the Stage I/II OSCC patients (data not shown).
Univariate and multivariate analyses of factors affecting DFS from
surgical resection
T status, IL-8(T) and CD163(IF) were significantly correlated with DFS (P50.028,
P50.007 and P50.002, respectively), and the N status, CRP, PNI and serum IL-8
tended to be correlated with DFS (P50.139, P50.080, P50.099 and P50.079,
respectively) by log-rank test (Table 4). Although high serum albumin level also
tended to be correlated with long DFS, PNI showed a higher p-value, and thus we
show the PNI data in Table 4.
The multivariate analysis was performed next. In the Cox’s hazard regression
test, significant correlations of N status, IL-8(T) and CD163(IF) with DSF was
observed (P50.002, P50.031 and P50.006, respectively) (Table 4). These three
factors may thus be independent factors affecting the DFS of OSCC patients.
Table 2. Relationship between mode of relapse and IL-8, CD163+cell-infiltration.
Local recurrence Post-operative LN metastasis
(p-value)
Serum IL-8 1.000 0.018*
IL-8(T) 0.089 0.001*
CD163(IF) 0.098 0.023*
T status 0.002* 0.423
H: high, L: low. LN: lymph node. The statistical relationships were detected by two-sided Fisher exact test.
*denotes p,0.05, indicating statistically significance.
doi:10.1371/journal.pone.0110378.t002
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Although 50 patients may not be enough for the most accurate analysis, we
believe that the current data shows this study to be worth for being extended to
larger patient groups.
Combinations of independent factors for predicting clinical
outcome of the OSCC patients
More useful biomarker(s) for predicting the clinical outcome of the resectable
OSCC patients may be established by combining independent factors. We found
that the DFSs were significantly longer in the patients with N0 and IL-8(T)(2),
with N0 and CD163(IF)Low, with IL-8(T)(2) and CD163(IF)Low, and with N0
and IL-8(T)(2) and CD163(IF)Low compared to those with N(+) or IL-8(T)(+),
with N(+) or CD163(IF)High, with IL-8(T)(+) or CD163(IF) high, and with N(+)
Table 3. Relationship between serum IL-8 and IL-8(T), between serum IL-8 and CD163(IF), between IL-8(T) and CD163(IF).
All patients Stage I/II Stage III/IV
(p-value)
Serum IL-8 vs. IL-8(T) 0.033* 0.018* 0.621
Serum IL-8 vs. CD163(IF) 0.038* 0.021* 0.640
IL-8 (T) vs. CD163 (IF) 0.0003* 0.0003* 0.193
The statistical relationships were detected by two-sided Fisher exact test. * denotes P,0.05, indicating statistically significance.
doi:10.1371/journal.pone.0110378.t003
Table 4. Univariate and multivariate analyses of factors affecting DFS after surgical resection of OSCC.
Variables No. of patients Log-rank (p-value) Cox’s hazard regression
Hazard
ratio 95%CI p-value
T status T1–2 35 0.028* 1.227 0.398–3.780 0.721
T3–4 15
N status N0 32 0.139 0.142 0.042–0.478 0.002*
N1–3 18
CRP >0.1 24 0.080 1.178 0.596–2.326 0.637
,0.1 26
PNI >50 26 0.099 0.786 0.452–1.368 0.394
,50 24
serum IL-8 >7 pg/ml 32 0.079 1.071 0.538–2.131 0.846
,7 pg/ml 18
IL-8(T) + 24 0.007* 0.274 0.084–0.889 0.031*
2 26
CD163(IF) High 25 0.002* 2.625 1.312–5.253 0.006*
Low 25
PNI: Prognostic Nutritional Index.
*denotes p,0.05, indicating statistically significance.
doi:10.1371/journal.pone.0110378.t004
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or IL-8(T)(+) or CD163(IF)High (P50.004, P50.017, P50.001 and P50.026,
respectively) (Fig. 3A–D).
Although the difference in DFS between the patients with IL-8(T)(2) and
CD163(IF)Low and those with IL-8(T)(+) or CD163(IF)High showed the best p-
value (P50.001), there were two patients in the IL-8(T)(2) and CD163(IF)Low
group who showed relapse events. Only one relapse event was observed in other
group with low relapse risk (Fig. 3A2D).
Interestingly, there was a marked and significant difference in DFS between the
patients with N0 and low serum IL-8 and those with N(+) or high serum IL-8
(P50.005) (Fig. 3E), and all of the patients with N0 plus low levels of serum IL-8
have shown no relapse event as of this writing.
Induction of CD163-positive M2 macrophages by IL-8
Based on the results from the study using patients’ specimens, we conducted the
in vitro experiments to examine whether IL-8 may induce CD163-positive M2
Figure 3. The combination of independent factors for predicting the DFS of OSCC patients. Differences in the DFS of OSCC patients with (A) N0 and
IL-8(T)(2) vs. N(+) or IL-8(T)(+), (B) N0 and CD163(IF)Low vs. N(+) or CD163(IF)High, (C) IL-8(T)(2) and CD163(IF)Low vs. IL-8(T)(+) or CD163(IF)High,
(D) N0 and IL-8(T)(2) and CD163(IF)Low vs. N(+) or IL-8(T)(+) or CD163(IF)High, (E) N0 and IL-8,7 pg/ml vs. N(+) or IL-8>7 pg/ml were calculated by log-
rank test. *P,0.05.
doi:10.1371/journal.pone.0110378.g003
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macrophages from human PBMC-derived adherent cells. Results showed that IL-8
statistically significantly enhanced the number of the CD163-positive cells induced
by M-CSF (Fig. 4A). In addition, we have also evaluated the induction of the cells
positive for CD206 which is another marker for M2 macrophages. We repeated
the experiments independently 4 times, and the similar results were obtained.
Representative data have been shown in Fig. 4B. IL-8 augmented the number of
CD206-positive cells which were induced by M-CSF. Because the values of the
leucocyte subset are generally different in a baseline by each independent donor,
statistical analysis is difficult to complete. Significant difference was obtained in
CD163-positive cell number, whereas was not obtained in CD206. Although Both
CD163 and CD206 are the markers of M2 macrophage, there may be some
difference in an expression pattern. Furthermore, it has been also indicated that
IL-8 significantly increased the production of IL-10 (Fig. 4C).
Figure 4. Generation of CD163-positive M2 macrophages by IL-8. Healthy donor-derived monocytes were treated with M-CSF (25 ng/ml) for 5 days and
then IL-4 (20 ng/ml) and IL-13 (20 ng/ml) for 2 days, or with M-CSF (25 ng/ml) for 5 days and then IL-8 (10 ng/ml) for 2 days. The cell-surface expression of
CD163 (A) and CD206 (B) of the cells was evaluated by using a flow cytometric analysis and IL-10 in the culture supernatants was measured by ELISA
(R&D Systems) (C). Bars denote SD of 5 samples.
doi:10.1371/journal.pone.0110378.g004
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These results strongly suggested that IL-8 may cause a poor clinical outcome in
OSCC patients via enhancing the generation of M2 macrophages which can
produce immune-suppressive cytokines such as IL-10.
Discussion
Factor(s) that can be detected by a peripheral blood examination are potential
biomarker candidate(s) for predicting therapeutic effects and patients’ prognoses
because it is technically easy to measure such factors, without a significant burden
on the patients. In addition, such biomarker(s) may be used for patients with
unresectable tumors since they can be obtained using only peripheral blood, not
surgical specimen. The findings from the present study indicate that a patient’s
serum IL-8 level may reflect his or her tumor microenvironment, which shows the
expression of IL-8 in cancer cells and the infiltration of CD163-positive
macrophages into the tumor invasive front. The serum IL-8 level may also be a
useful biomarker at least in patients with early-stage (Stage I/II) OSCC. The DFS
rate is 100% in early-stage OSCC patients with low levels of serum IL-8. Adjuvant
and/or neo-adjuvant therapies may be necessary for patients with high levels of
serum IL-8, even if they have early-stage OSCC. Our present findings also strongly
suggest that IL-8 expression and the infiltration of CD163-positive M2
macrophages in the tumor microenvironment might be biomarkers for affecting
and for predicting the clinical outcome of patients with any stage of OSCC,
including advanced OSCC (Stage III/IV). Our statistical analyses revealed that
there was a significant and strong difference in the DFS between the patients who
showed N0 and low serum IL-8 and those who showed N(+) or high serum IL-8
(P50.005). No relapse event has occurred in the patients with N0 plus low levels
of serum IL-8. The combination of N status with the circulating IL-8 level may be
a new criterion for discriminating high-risk and low-risk patients with resectable
OSCC. In addition, the results of the present multivariate analysis indicate that N
status, IL-8 expression in the tumor and the infiltration of CD163-positive
macrophages are independent factors which can affect and predict the clinical
outcome of OSCC patients. Studies with larger numbers of patients are necessary
to determine which combination is the most useful biomarker for OSCC patients,
and a multicenter study toward this end is now being conducted.
As shown in Table 3, serum IL-8 was significantly correlated with IL-8(T) and
with CD163(IF) in all stage patients (P50.033 and P50.038) as well as in Stage I/
II patients (P50.018 and P50.021). IL-8(T) and CD163(IF) was also significantly
correlated in all stage patients (P50.0003). Most of Stage III/IV patients (18 of 23
patients) showed high serum IL-8, and the tendency that serum IL-8 levels in
Stage III/IV patients were higher than in Stage I/II patients was observed
(P50.077). Whereas, no correlation between clinical stage and IL-8(T) as well as
CD163(IF) (P50.773 and P51.000). Therefore, serum IL-8 might not be
correlated with IL-8(T) as well as with CD163(IF) in Stage III/IV patients
(P50.621 and P50.640).
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In the present in vitro experiments, IL-8 induced CD163-positive M2
macrophages producing IL-10. This is the first report which shows direct
induction of M2 macrophages by IL-8 although it is known that M2 macrophages
secrete IL-8 [18, 19]. It is possible that IL-8 produced by cancer cells leads to poor
clinical outcomes of patients with OSCC via the generation and activation of M2
macrophages. It has been reported that IL-8 and VEGF secreted by the
alternatively activated macrophages accelerate tumor expansion via angiogenesis
[20]. The immunohistochemical staining of the same specimens as those used in
the present study revealed that the number of CD34-positive endothelial cells in
the tumor tissues was significantly correlated with poor clinical outcomes of the
OSCC patients; however, there was no significant correlation between the CD34-
positive cell number and IL-8 expression or CD163-positive M2 macrophage-
infiltration in the tumor tissues (authors’ personal communications). Thus, IL-8
and CD163-positive macrophages might elicit tumor relapse and/or post-
operative cervical LN metastasis via any other mechanisms besides tumor
angiogenesis (e.g., the suppression of antitumor immunity) in the tumor
microenvironment.
In the present study, Foxp3-positive cell infiltration in the tumor tissue did not
correlate with the patients’ survival or with other immunological parameters such
as serum IL-8, IL-8(T) and CD163(IF). Foxp3-positive T cells are conventionally
thought to suppress antitumor immunity, resulting in poor clinical outcomes in
cancer patients. However, several recent reports demonstrated that cancer patients
with high levels of tumor-infiltrating Foxp3-positive cells showed favorable
clinical outcomes [21], and that anti-inflammatory cytokines (e.g., IL-10 and
transforming growth factor-beta [TGF-b]) produced by Foxp3+ Tregs suppress
IL-6, IL-8 and TNF-a [22] which may accelerate tumor progression. The role of
Foxp3-positive cells in the clinical outcome of cancer patients is remains
controversial.
Since the present findings also strongly suggest that IL-8 is not only a
prognostic marker but also a factor that may contribute to a poor prognosis, the
agents that can block the activity of IL-8 may be useful for improving the clinical
outcome of patients with high IL-8 levels. We are now preparing a clinical trial for
OSCC patients using IL-8 inhibitors including a humanized anti-human IL-8
monoclonal antibody [23] and some nutritional supplements that can suppress
the upstream signals of IL-8 production, e.g. NF-kB and STAT3 [24, 25]. We
expect that the ongoing prospective study will elucidate the prognostic and
predictive significance of IL-8 reflecting the tumor microenvironment with the
infiltration of CD163-positive M2 macrophages, and that it will be possible to
conduct a clinical trial of an IL-8 inhibitor for high-risk OSCC patients.
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